CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 17 enrolled
Drug / intervention
Memantine +1 moredrug
Likely dose
Memantine 10mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00255086
NCT00255086Phase 3Completed
CompareCT.gov

The Effect of Memantine on Brain Structure and Chemistry in Alzheimer's Disease Patients: A Randomized, Placebo-Controlled, 52-Week Clinical Trial

Stanford University·interventional·Posted Nov 17, 2005·Updated Apr 7, 2017

In Brief

A Phase 3 clinical trial evaluating Memantine and Placebo pill for Alzheimer Disease. Completed, enrolled 17 participants across 1 site.

Detailed Summary

The aim of the proposed study is to determine if the NMDA receptor antagonist memantine has a neuroprotective effect on magnetic resonance spectroscopic imaging (MRS) measures of brain NAA and magnetic resonance imaging (MRI) volumetric measures of hippocampal volume. In secondary analyses, we will determine if measures of clinical stabilization produced by memantine in the treatment of Alzheimer's disease (AD) parallels stabilization of MRS measures of brain NAA and MRI volumetric measures of hippocampal volume.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAlzheimer Disease
CountriesUnited States
CollaboratorsPalo Alto Veterans Institute for Research, Forest Laboratories

Timeline

Phase 3CompletedFinished
20052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedNov 17, 2005
Enrollment StartMay 1, 2005
Primary CompletionJun 1, 2009
Study CompletionFeb 1, 2010
TodayJul 2, 2026
Enrollment to primary: 4.1 yearsPosted 20.6 years ago

Interventions

Memantinedrug

10mg Memantine

Placebo pilldrug

10mg placebo pill